The fifth annual EuroMedtech™ partnering conference to be held May 7–8 in Duesseldorf, Germany will feature executive panelists who will share insight on business development models and strategies for success in the medtech industry. As the leading partnering event for medical devices and technology, the conference is a go-to event for leaders in medical technology, medtech decision makers and investors.
The opening plenary is thematic of the event, and is entitled “Inside innovation: How developments in financing, strategy and collaboration are driving the medtech machine.” Plenary panelists, including Regina Hodits, General Partner at Wellington Partners; Angelo de Rosa, Head of Strategy and Business Development at Medtronic; Townsend Goddard, Senior Director, Business Development and Strategy for Stryker; Mark Hitchman, Managing Director at Toshiba Medical Systems UK; Cécile Vienney, CEO at HyPrevention; and Bill Welch, Director at Abbott Ventures, Inc., will discuss new collaboration models that help companies develop an edge in the medtech industry.
"Innovative products are not only changing the medical practice as in minimal invasive surgeries, but are also demanding changes in business models," said Hodits. “Market opportunities for medical devices and diagnostics – with the potential to reduce overall financial burden for healthcare providers – are here to stay; and venture financed companies have demonstrated that they can successfully launch products and get them reimbursed in Europe. Based on these sound fundamentals, we see a strong and attractive deal flow for healthcare investors in Europe and believe there is potential for sustainable growth in the sector. But we will all need to adapt in order to cope with ever higher demands of an aging population and associated fierce cost pressure on the health care systems. This will be one topic of the plenary.”
“If we hope to see improvements in healthcare in terms of market accessibility, we are going to have to continue pursuing partnerships that address successful implementation of medtech solutions,” said Hitchman. “Product and technological innovation is important, but the industry will be driven by the business strategies that allow us to attract investors and key partners, while maintaining a competitive edge.”
“2012 was a big year for medtech mergers and acquisitions, and we are also still seeing great opportunities for medtech companies in emerging markets, in part due to aging populations’ demand for implantable devices,” said Vienny. “Pricing pressures and other myriad challenges still exist, but the improving economic outlook combined with creative business models arising from leaner times have created partnership opportunities that will shape medtech going forward.”
EuroMedtech is Europe’s leading medical technology partnering conference providing collaboration opportunities to medtech decision makers and investors. Participants meet with numerous potential partners and discuss in- and out-licensing, financing and other collaborative programs. EuroMedtech 2013 will again feature the popular Next Generation Presentation track for young entrepreneurial companies and the Company Presentation track for innovative medtech corporations.
“A group of innovative medtech companies from West Sweden will be represented at EuroMedtech 2013,” said Iris Öhrn, from Business Region Gothenburg. “The growth of the medical device and therapeutics industry in Sweden and northern European countries is strong, and our companies are looking for new business alliances and partnerships for bringing their novel products to market and successfully growing their existence business.”
Hosted by EBD Group, the leading partnering firm for the global life science industry,EuroMedtech caters to companies involved in all parts of the advanced medical technology industry, from those serving mainline therapeutic categories such as drug delivery and augmented intervention in medicine, through diagnostics, imaging and eHealth to those involved in platform technologies such as micro and nanotechnological tools and implantable devices.
About EBD Group
EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group’s partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success.
EBD Group’s conferences are run with the support of leading corporations and international trade associations and include:
● BIO-Europe® and BIO-Europe Spring®, Europe’s largest life science partnering conferences, supported by the Biotechnology Industry Organization (BIO)
● BioPharm America™, the fastest growing partnering event in North America
● Biotech Showcase™, a unique forum in San Francisco for presenting to investors and business development executives, co-produced with Demy-Colton Life Science Advisors
● BioEquity Europe, the investor conference co-organized with BioCentury Publications and BIO
● ChinaBio® Partnering Forum, the first dedicated biotech/pharma partnering conference in China, co-produced with ChinaBio® LLC
● EuroMedtech™, EBD Group’s partnering event for the innovative medical technology industry
● Partnering for Global Impact®, a new partnering conference providing an innovative forum to partner, identify and generate social and philanthropic investment and funding opportunities
EBD Group’s sophisticated web-based partnering service, partneringONE®, is also used as the partnering engine at numerous third-party events around the world, andpartnering360® is the open online community of life science dealmakers that enhances partnering experiences all year long.
Outside of the conference format, EBD Group’s consultants provide hands-on assistance for firms seeking to in- or out-license products and technologies.
EBD Group has offices in the USA and Europe.
